Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

325.62 +12.90 (+4.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study
Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical... 
Via Benzinga
Where Eli Lilly Stands With Analysts
Within the last quarter, Eli Lilly (NYSE:LLY) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1 0 Somewhat... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Raymond James raised Nutrien Ltd. (NYSE: NTR) price target from $75 to $82. Nutrien shares fell 1.1% to trade at $63.05 on Tuesday. Credit Suisse lifted the price target on... 
Via Benzinga
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
The Latest Barron's Picks And Pans: DocuSign, UPS, Taiwan Semiconductor And More
The cover story in this weekend's Barron's examines how teenage traders are shaking up the market. Other featured articles discuss which drugmakers benefit from a new... 
Via Benzinga
Eli Lilly's Internal Probe Clears Its COVID-19 Drug Plant; Memo Says Company Did Not Make False Statements: Reuters
Eli Lilly and Co (NYSE: LLY) revealed last month that the U.S. Department of Justice (DOJ) issued a subpoena into its manufacturing facility in Branchburg, New... 
Via Benzinga
Topics Law Enforcement
Exposures COVID-19 Legal
8 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
S&P 500 Hits Record High; Biogen Alzheimer's Drug, Tesla, Apple, RH, GameStop In Focus: Weekly Review
The S&P 500 hit a new high this week. The FDA OK'd a Biogen Alzheimer's drug. Tesla, Apple, RH, GameStop were in focus. 
Via Investor's Business Daily
Topics Stocks
Exposures Product Safety US Equities
Why Biogen, Lilly, and Prothena Stocks Soared This Week
The FDA's approval of Biogen's Aduhelm in treating Alzheimer's disease boosted all three stocks. 
Via The Motley Fool
Exposures Product Safety
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (... 
Via Benzinga
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%. The Biogen Analysts:... 
Via Benzinga
Exposures Product Safety
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
FDA surprise
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
Exposures Product Safety
Why Eli Lilly Stock Soared Today
Biogen's stunning win of FDA approval for aducanumab spurred investors' excitement about Lilly's prospects for its Alzheimer's disease candidate. 
Via The Motley Fool
Exposures Product Safety
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
Exposures Product Safety
Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor
Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to... 
Via Talk Markets
3 Dividend-Paying Pharmaceutical Stocks to Buy This Summer
The pharmaceutical industry has benefited from much investor attention amid the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
Ahead Of Judgement Day, FDA Faces Test with Biogen's Alzheimer's Drug Decision
U.S. regulators are slated to decide by Monday whether to approve Biogen Inc’s (NASDAQ: BIIB) much-talked-about Alzheimer’s disease drug, aducanumab.... 
Via Benzinga
Exposures Product Safety
Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers
Eli Lilly & Co’s (NYSE: LLY) R&D partner Merus N.V. (NASDAQ: MRUS) have revealed some new data at ASCO21 for an in-house program,... 
Via Benzinga
Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC: IVBXF) and Eli Lilly And Co's (NYSE: LLY)... 
Via Benzinga
What's In Store For Biogen Stock If Alzheimer's Drug Aducanumab Nabs FDA Nod?
Biogen stock rose Wednesday after an analyst suggested its controversial Alzheimer's treatment, aducanumab, could gain U.S. approval later this month. 
Via Investor's Business Daily
Exposures Product Safety
Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial
Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of... 
Via Benzinga
Hot Stuff In The Market – Psychotropic Drugs
Last year around this time, we have been facing our worst fears - our existence and health have been put on the spot. Since then, Covid-19 has forced us to accept a “new normal” and has led to a big... 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Anika Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
15 Words From Vir Biotechnology's CEO May Mean Market Dominance
Vir's antibody treatment is addressing one of the biggest COVID challenges. 
Via The Motley Fool
Exposures COVID-19
Justice Department Opens Probe In Presumed lapses at Eli Lilly's COVID-19 Drug Plant: Reuters
The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (NYSE: LLY) focused on alleged manufacturing irregularities and records... 
Via Benzinga
Exposures COVID-19
Eli Lilly Slapped With DoJ Subpoena Over COVID-19 Drug Manufacturing Plant: Reuters
Eli Lilly and Co (NYSE: LLY) has received a subpoena from the U.S. Department of Justice related to its New Jersey plant that makes its COVID-19 treatment,... 
Via Benzinga
Topics Law Enforcement
Exposures COVID-19 Legal
The Surprising Move Vir Stock Made After Winning Covid Drug Authorization
GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. 
Via Investor's Business Daily
Exposures COVID-19
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.